Subject(s)
Amdinocillin Pivoxil/administration & dosage , Staphylococcal Infections/drug therapy , Urinary Tract Infections/drug therapy , Humans , Nalidixic Acid/administration & dosage , Remission, Spontaneous , Staphylococcal Infections/microbiology , Trimethoprim/administration & dosage , Urinary Tract Infections/microbiologyABSTRACT
Low-dose nalidixic acid (0.66 g) in combination with 4 g of sodium citrate (NAC) was evaluated in acute lower UTI. In college-age females (n = 24) given NAC every 8 h for 3 days the nalidixic acid (NA) susceptible infecting strain was eradicated in 100% of the patients and recurrence during the 1 month follow-up period occurred in 1 case (5%) classified as relapse. In a following study the corresponding rates in general practice (GP) patients (n = 71) were 90% and 17%, respectively, irrespective of treatment with NAC every 12 h for 3 days or 5 days. The failures observed in GP were due to persistence of (or immediate reinfection by) the original infecting strain (4%) or its NA resistant mutant (6%). Emergence of NA resistance was associated with high age of the patient and a high incidence of NA resistant mutants in the infecting Escherichia coli strain. NA susceptible failure and recurrence during follow-up occurred primarily in younger GP patients. The recurrences were equally often classified as relapse (6 cases) as reinfection (5 cases). About 20% of the patients reported rather innocuous transient side effects of NAC and interruption of medication occurred in 1 case (0.6%).
Subject(s)
Antacids/therapeutic use , Bacteriuria/drug therapy , Citrates/therapeutic use , Nalidixic Acid/therapeutic use , Urinary Tract Infections/drug therapy , Adolescent , Adult , Aged , Antacids/administration & dosage , Citrates/administration & dosage , Citric Acid , Drug Administration Schedule , Drug Combinations , Female , Humans , Middle Aged , Nalidixic Acid/administration & dosage , RecurrenceABSTRACT
The effect of a 3-day course of nalidixic acid was studied in 82 women, presenting with the dysuria-frequency syndrome and significant bacteriuria, mostly Escherichia coli sensitive to nalidixic acid. 62/76 patients (82%) that could be evaluated about 1 week after initiation of therapy were subjectively cured. Negative urinary cultures were found in 64/76 patients (84%). Two patients (2.4%) developed resistance to nalidixic acid. Bacteriological cure rate was 76% of 71 patients that could be controlled 1 month after the initiation of therapy. Nalidixic acid in the used granulate preparation initiated only mild side-effects.
